The results of a 2016 Phase III trial of the monoclonal antibody bevacizumab (Avastin) have established another option for treatment for those suffering from malignant pleural mesothelioma. Angiogenesis, which is the formation of new blood vessels, plays a key role in mesothelioma because it allows the tumors and cancer to[…]
From the blog
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
Purpose: This randomized phase I/II trial studies the side effects and how well pembrolizumab with or without anetumab ravtansine work in treating patients with mesothelin-positive pleural mesothelioma. Monoclonal antibodies, such as anetumab ravtansine and pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
Surgical Techniques for Mesothelioma
While surgical techniques are not the most common effort when it comes to treating mesothelioma, the pleurectomy/decortication (P/D) is a technique that has been the most successful over the years. A recent study took a look at the different surgical techniques that can be used with P/D and noted the[…]
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Purpose: The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
Success in Lung Cancer Treatment Gives Hope to Mesothelioma Patients
The latest success concerning a treatment for non- small cell lung cancer (NSCLC) has scientists and researchers hopeful that the same treatment can be applied to mesothelioma victims. The Phase III trial for Alecensa (alectinib), while currently not recruiting participants, is on-going and results thus far have shown to be[…]
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505)
Purpose: Patients with pleural mesothelioma that can not be surgically removed will receive durvalumab, in combination with standard chemotherapy of pemetrexed and cisplatin as first-line treatment.
Durvalumab is a type of drug called a monoclonal antibody (a type of protein). Laboratory tests show that it works by allowing the immune system to detect your cancer and reactivates the immune response. This may help to slow down the growth of cancer or may cause cancer cells to die. The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS).
Treatment Used In Multiple Sclerosis May Be Used In Mesothelioma
Although still in the preliminary stages, scientists and researchers are excited to announce recent research involving a treatment that is used for certain types of multiple sclerosis (MS) and its effects on combating mesothelioma. This therapeutic agent is called Immune System Modulator FTY720 (fingolimod) and is interestingly derived from a[…]
Nintedanib and Pembrolizumab – Hope for Mesothelioma Patients
The latest findings in cancer treatments for the often fatal mesothelioma have scientists and researchers hopeful that they are one step closer in finding a consistent, effective treatment for the asbestos-caused cancer. The LUME-Meso Phase II trial for patients with malignant pleural mesothelioma focused on the administration of the triple angiokinase[…]
National Asbestos Awareness Week: April 1 – April 7, 2017
On March 29, 2017 the U.S. Senate passed S. Res.98; a resolution designating the first week of April as “National Asbestos Awareness Week” in an attempt to warn and educate the public about asbestos exposure and its deadly health effects. Despite it being a known carcinogen and its ban in[…]
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Purpose: his research study is studying a pair of immunotherapies as a possible treatment for malignant pleural mesothelioma. The drugs involved in this study are Durvalumab and Tremelimumab.
Skip to content